Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lamivudine Clear all
Completed Phase 3 Interventional

A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

NCT00057265
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
telbivudine or lamivudine
Drug
Lead sponsor
Novartis
Industry
Eligibility
16 Years to 70 Years
Timeline
Started 2003
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

NCT04552795
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
3TC
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

NCT00001644
View directory record Official record
Conditions
HIV Infection
Interventions
Indinavir, Zidovudine, Lamivudine, Nevirapine, Blood testing, Lymph node biospy, Leukapheresis
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 25, 2026, 4:58 PM EDT
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

NCT00335270
View directory record Official record
Conditions
HIV
Interventions
fos-amprenavir calcium, ritonavir, abacavir/lamivudine as Epzicom
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

NCT00000888
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
5
States / cities
Miami, Florida • Detroit, Michigan • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000878
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

NCT00491556
View directory record Official record
Conditions
HIV Infections
Interventions
Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 25, 2026, 4:58 PM EDT
Suspended Phase 2 Interventional

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00004998
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
9
States / cities
Clearwater, Florida • Fort Lauderdale, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

NCT02105987
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC, Ongoing cART regimen
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
87
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

NCT00075231
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra® (lopinavir/ritonavir), Combivir® (lamivudine, zidovudine), Sustiva® (efavirenz)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2006 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Blood Levels of Abacavir in HIV Infected Adolescents

NCT00087945
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Abacavir sulfate, lamivudine, and zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
19
States / cities
Alhambra, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional

DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116415
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
efavirenz; didanosine EC; lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

NCT00000918
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

NCT02582684
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Dolutegravir, Lamivudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Combivir for Patients With Primary Biliary Cirrhosis

NCT00490620
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Combination antiviral therapy, Placebo
Drug
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

NCT00380159
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)-1 Infection
Interventions
Elvucitabine, Lamivudine, Emtricitabine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

NCT00000901
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

NCT00002215
View directory record Official record
Conditions
HIV Infections
Interventions
Emivirine, Nelfinavir mesylate
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

NCT00440947
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
62
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

NCT00002168
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • Torrance, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 25, 2026, 4:58 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

NCT02263079
View directory record Official record
Conditions
Pediatric Immuno-Tolerant Chronic Hepatitis B
Interventions
Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 25, 2026, 4:58 PM EDT